| Status | Suspended |
| Process | STA pre-2018 |
| Referral date | 01 July 2012 |
| Topic area |
|
| Description |
Scoped as part of batch 23 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 14 November 2012 |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | Andrew Dillon |
| Project manager: | Kate Moore |
| Technical Lead: | Pilar Pinilla-Dominguez |
Consultees
| Manufacturers/sponsors | Vivus (phentermine with topiramate) |
| Others | Arden PCT Cluster |
| Department of Health | |
| Welsh Government | |
| Patient/carer groups | HEART UK |
| Professional groups | Royal College of Nursing |
| Royal College of Physicians | |
| The Obesity Management Association |
Commentators
| Associated guideline groups | None |
| Associated public health groups | None |
| Comparator manufacturers | GlaxoSmithKline (orlistat) (confidentiality agreement not signed, not participating) |
| Roche Products (Orlistat) (confidentiality agreement not signed, not participating) | |
| Teva UK (orlistat) (confidentiality agreement not signed, not participating) | |
| Evidence Review Group | National Institute for Health Research Health Technology Assessment Programme |
| School of Health and Related Research Sheffield (ScHARR) | |
| General | Commissioning Support Appraisals Services |
| Department of Health,Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| Relevant research groups | Cochrane Heart Group |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 April 2013 |
The Department of Health asked the Institute to conduct an appraisal of phentermine with topiramate for the treatment of obesity and overweight and to provide guidance on its use to the NHS in England and Wales. The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently re-examined its initial negative opinion for phentermine and has confirmed the refusal of the marketing authorisation. NICE has therefore decided to suspend this appraisal indefinitely. As this topic has been referred to the Institute we will continue to monitor any developments and will update this webpage if the situation changes. |
| 6 November 2012 |
Following an update on the regulatory status of this technology which has received a negative CHMP opinion, we are suspending the appraisal whilst we consider the next steps. Consequently the discussion of this appraisal at the Committee meeting on 27 February 2013 has been cancelled. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance